Amer Zeidan, MBBS, MHS, of Yale University, discusses results of the phase III IMerge trial, which he presented during the 2023 American Society of Clinical Oncology Annual Meeting. The randomized, double-blind, placebo-controlled study evaluated imetelstat in patients with heavily transfusion dependent non-del(5q) lower-risk myelodysplastic syndromes who relapsed or were refractory to erythropoiesis stimulating agents. ...
Advertisement
Advertisement
Dr. Venugopal, who was not involved in the study, discusses the results and implications of the phase III trial.
Dr. Nastoupil reflects on the experiences that led her to study disparities in lymphoma and her hopes for the future.
Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 ASCO meeting.
Health care disparities have been an "ongoing issue" for patients with cancer, especially in multiple myeloma.
At the ASCO meeting, researchers presented results of the trial with 22 months of follow-up.
The ongoing, long-term CARTITUDE study will continue to follow these patients for safety and survival.
AML Awareness Month is marked each June.
The phase III study will evaluate pirtobrutinib versus ibrutinib in patients with CLL or SLL.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
ccr.cancer.gov
Clinical trial researching CAR T-cell therapy for leukemia and lymphoma
National Cancer Institute
National Cancer InstituteAcute lymphoblastic leukemi
#ALL
#CART
American Society of Hematology
Impact of Type of Induction Therapy on Outcomes in Older Adults with AML after Allogeneic
Hagop Kantarjian, MD
Hagop Kantarjian, MDLIT plus venetoclax is associated with favorable pos
#AML
ScienceDirect
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene Rx
Chimeric Antigen Receptor T-Cell (CAR-T) & Gene RxVenetoclax is a highly selective B-cell lymphoma-2 (
#AML
American Society of Hematology
How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia
Faheema Hasan
Faheema HasanSystemic treatment of adult patients with acute lymp
#ALL
